Showing 1 to 12 of 20 results
Weight-Loss Drugs Halve Heart Failure Hospitalizations and Deaths
A large-scale study reveals that GLP-1 agonists, semaglutide and tirzepatide, significantly reduce hospitalizations and mortality risk by 42% and 58%, respectively, in obese heart failure patients with type 2 diabetes.
Weight-Loss Drugs Halve Heart Failure Hospitalizations and Deaths
A large-scale study reveals that GLP-1 agonists, semaglutide and tirzepatide, significantly reduce hospitalizations and mortality risk by 42% and 58%, respectively, in obese heart failure patients with type 2 diabetes.
Progress
32% Bias Score
Wegovy's 7.2mg Dose Shows 20.7% Weight Loss in Obese Individuals: Novo Nordisk
Novo Nordisk's STEP UP trial, presented at the ADA 2024 Scientific Sessions, demonstrated that a 7.2mg dose of semaglutide (Wegovy) led to a 20.7% average weight loss in obese individuals without diabetes after 72 weeks, with a third achieving at least 25% weight reduction compared to placebo; the c...
Wegovy's 7.2mg Dose Shows 20.7% Weight Loss in Obese Individuals: Novo Nordisk
Novo Nordisk's STEP UP trial, presented at the ADA 2024 Scientific Sessions, demonstrated that a 7.2mg dose of semaglutide (Wegovy) led to a 20.7% average weight loss in obese individuals without diabetes after 72 weeks, with a third achieving at least 25% weight reduction compared to placebo; the c...
Progress
52% Bias Score
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Progress
52% Bias Score
Weight Loss Injections Could Boost UK Economy by £4.5 Billion
Research presented at the European Congress on Obesity in Málaga estimates that providing semaglutide to eligible UK residents could boost the economy by £4.5 billion due to increased productivity among 2,660 trial participants who gained an average of 17 extra workdays annually, offsetting some of ...
Weight Loss Injections Could Boost UK Economy by £4.5 Billion
Research presented at the European Congress on Obesity in Málaga estimates that providing semaglutide to eligible UK residents could boost the economy by £4.5 billion due to increased productivity among 2,660 trial participants who gained an average of 17 extra workdays annually, offsetting some of ...
Progress
44% Bias Score
Wegovy Ingredient Shows Promise in Treating Fatty Liver Disease
Research published in the New England Journal of Medicine shows that semaglutide, the active ingredient in Wegovy, significantly reduced liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH), a fatty liver disease affecting an estimated 1.5% to 6.5%...
Wegovy Ingredient Shows Promise in Treating Fatty Liver Disease
Research published in the New England Journal of Medicine shows that semaglutide, the active ingredient in Wegovy, significantly reduced liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH), a fatty liver disease affecting an estimated 1.5% to 6.5%...
Progress
48% Bias Score
Semaglutide Linked to Reduced Dementia Risk in Major Studies
Two large-scale studies suggest that the weight-loss drug semaglutide, found in Wegovy and Ozempic, may significantly lower the risk of developing dementia, offering a potential preventative measure against a condition costing the UK £42 billion annually.
Semaglutide Linked to Reduced Dementia Risk in Major Studies
Two large-scale studies suggest that the weight-loss drug semaglutide, found in Wegovy and Ozempic, may significantly lower the risk of developing dementia, offering a potential preventative measure against a condition costing the UK £42 billion annually.
Progress
32% Bias Score
Counterfeit Weight-Loss Drugs: A Global Health Crisis
The high demand for weight-loss drugs like Ozempic has created shortages, leading to a surge in counterfeit medications globally, with the World Health Organization estimating 10% of medicines are fake; this is fueled by compounding pharmacies and exacerbated by inadequate consumer awareness.
Counterfeit Weight-Loss Drugs: A Global Health Crisis
The high demand for weight-loss drugs like Ozempic has created shortages, leading to a surge in counterfeit medications globally, with the World Health Organization estimating 10% of medicines are fake; this is fueled by compounding pharmacies and exacerbated by inadequate consumer awareness.
Progress
44% Bias Score
UK: Pregnancy Risk Linked to Weight-Loss Drugs and Birth Control Pills
In the UK, 40 women became pregnant while taking birth control pills and weight-loss drugs (Mounjaro, Saxenda, Ozempic/Wegovy); the MHRA warns of a potential link, advising against relying solely on oral contraceptives when using these drugs.
UK: Pregnancy Risk Linked to Weight-Loss Drugs and Birth Control Pills
In the UK, 40 women became pregnant while taking birth control pills and weight-loss drugs (Mounjaro, Saxenda, Ozempic/Wegovy); the MHRA warns of a potential link, advising against relying solely on oral contraceptives when using these drugs.
Progress
64% Bias Score
Weight Regain After Stopping Weight-Loss Injections: An Oxford Study
A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.
Weight Regain After Stopping Weight-Loss Injections: An Oxford Study
A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.
Progress
48% Bias Score
Wegovy Shows Promise in Treating Serious Liver Disease
A Novo Nordisk-funded trial shows Wegovy effectively treated MASH in 63% of 800 patients across 37 countries, significantly improving liver inflammation and fibrosis, leading to potential FDA approval by year-end.
Wegovy Shows Promise in Treating Serious Liver Disease
A Novo Nordisk-funded trial shows Wegovy effectively treated MASH in 63% of 800 patients across 37 countries, significantly improving liver inflammation and fibrosis, leading to potential FDA approval by year-end.
Progress
44% Bias Score
Semaglutide Shows Promise in Treating Metabolic-Associated Fatty Liver Disease
A new study published in the New England Journal of Medicine reveals that semaglutide, a key ingredient in popular weight-loss drugs, significantly improved liver inflammation and scarring in patients with metabolic-associated fatty liver disease (MASH) after 72 weeks, with 33% of patients on semagl...
Semaglutide Shows Promise in Treating Metabolic-Associated Fatty Liver Disease
A new study published in the New England Journal of Medicine reveals that semaglutide, a key ingredient in popular weight-loss drugs, significantly improved liver inflammation and scarring in patients with metabolic-associated fatty liver disease (MASH) after 72 weeks, with 33% of patients on semagl...
Progress
40% Bias Score
New Obesity Drugs Achieve Significant Weight Loss, Challenging Traditional Approaches
New drugs, such as semaglutide and tirzepatide, are revolutionizing obesity treatment by mimicking key hormones that regulate appetite and metabolism, achieving significant weight loss (up to 25%) in clinical trials, while traditional methods often fail in the long term; this has led to a surge in p...
New Obesity Drugs Achieve Significant Weight Loss, Challenging Traditional Approaches
New drugs, such as semaglutide and tirzepatide, are revolutionizing obesity treatment by mimicking key hormones that regulate appetite and metabolism, achieving significant weight loss (up to 25%) in clinical trials, while traditional methods often fail in the long term; this has led to a surge in p...
Progress
48% Bias Score
Showing 1 to 12 of 20 results